Arcadia Biosciences Inc's Suppliers recorded an increase in sales by 39.02 % year on year in Q2 2026, sequentially sales grew by 30.3 %, Arcadia Biosciences Inc's cost of sales deteriorated by -1.46 % year on year, sequentially cost of sales grew by 16 % in Q2.
Arcadia Biosciences Inc's Suppliers recorded an increase in sales by 39.02 % year on year in Q2 2026, sequentially sales grew by 30.3 %, Arcadia Biosciences Inc's cost of sales deteriorated by -1.46 % year on year, sequentially cost of sales grew by 16 % in Q2.
University of Alberta. We hold an exclusive license from University of Alberta
to the patent portfolio that formed the basis of our NUE program, which began
in 2002. In exchange for an upfront license fee and royalties on sublicense
revenues and net product sales (which are capped at an aggregate amount in the
mid-seven figures), and subject to the University’s right to perform academic
research using the technology, we exclusively control all research, development,
commercialization, and sublicensing of the patented technology globally for
all crops.
Blue Horse Labs. In conjunction with a sponsored research and development agreement
entered into in 2003, we obtained an exclusive license from Blue Horse Labs,
an affiliate entity of our majority stockholder, Moral Compass Corporation,
for technology related to several of our development programs. Under the sponsored
research and development agreement, Blue Horse Labs has an ownership right in
patents covering technology that was developed using Blue Horse Labs funds,
including certain NUE and GLA safflower patents. In the corresponding license
agreement, in exchange for a single-digit royalty on net revenues and management
of all aspects of the patent portfolio, we exclusively control all research,
development, commercialization, and sublicensing of the patented technology
globally for all crops.
University of California, Davis. Our WUE technology was developed under an exclusive
option agreement with the University of California, Davis, pursuant to which
we exercised our right to secure an exclusive license in 2010. We also hold
an exclusive license from University of California, Davis, to the patent portfolio
that forms the basis of our Salinity Tolerance program. In exchange for an upfront
license fee, license maintenance fees, and royalties on sublicense revenues
and net product sales, we exclusively control all for-profit research, development,
commercialization, and sublicensing of the patented technology globally for
all crops.
University of Toronto. We hold an exclusive license from University of Toronto
to the patent portfolio that forms the basis of our Salinity Tolerance program.
In exchange for an upfront license fee, a royalty on revenues, and payment of
all costs associated with the patent portfolio, and subject to the University’s
right to use the technology for research and teaching purposes, we exclusively
control all for-profit research, development, commercialization and sublicensing
of the patented technology globally for all crops.
Abbott. We entered into a license and development agreement with Abbott in 2003
under which we have been granted limited exclusive rights to Abbott’s
portfolio of U.S. and foreign patents relating to the development of plant-based
sources of GLA, ARA and essential fatty acids. Under this agreement, we provide
Abbott with preferential access to commercial products from our GLA and ARA
safflower programs, as well as the right to receive royalty payments on product
sales to third parties, in exchange for the licenses to Abbott’s intellectual
property rights.
Dow AgroSciences. In December 2015, we announced the entry into a strategic
collaboration with Dow AgroSciences to develop and commercialize new yield traits
and trait stacks in corn. The collaboration leverages our platform of abiotic
stress traits with Dow AgroSciences’ enabling technology platforms, input
traits, regulatory
17
capabilities and commercial channels. As part of the strategic partnership,
we negotiated non-exclusive access to Dow AgroSciences’ EXZACT™
Precision Technology Platform to enhance and accelerate the development of trait
stacks. Dow AgroSciences has developed the EXZACT™ Precision Technology
Platform under an exclusive license and collaboration agreement in plants with
Sangamo BioSciences, Inc.
Arcadia Biosciences Inc's Comment on Supply Chain
University of Alberta. We hold an exclusive license from University of Alberta
to the patent portfolio that formed the basis of our NUE program, which began
in 2002. In exchange for an upfront license fee and royalties on sublicense
revenues and net product sales (which are capped at an aggregate amount in the
mid-seven figures), and subject to the University’s right to perform academic
research using the technology, we exclusively control all research, development,
commercialization, and sublicensing of the patented technology globally for
all crops.
Blue Horse Labs. In conjunction with a sponsored research and development agreement
entered into in 2003, we obtained an exclusive license from Blue Horse Labs,
an affiliate entity of our majority stockholder, Moral Compass Corporation,
for technology related to several of our development programs. Under the sponsored
research and development agreement, Blue Horse Labs has an ownership right in
patents covering technology that was developed using Blue Horse Labs funds,
including certain NUE and GLA safflower patents. In the corresponding license
agreement, in exchange for a single-digit royalty on net revenues and management
of all aspects of the patent portfolio, we exclusively control all research,
development, commercialization, and sublicensing of the patented technology
globally for all crops.
University of California, Davis. Our WUE technology was developed under an exclusive
option agreement with the University of California, Davis, pursuant to which
we exercised our right to secure an exclusive license in 2010. We also hold
an exclusive license from University of California, Davis, to the patent portfolio
that forms the basis of our Salinity Tolerance program. In exchange for an upfront
license fee, license maintenance fees, and royalties on sublicense revenues
and net product sales, we exclusively control all for-profit research, development,
commercialization, and sublicensing of the patented technology globally for
all crops.
University of Toronto. We hold an exclusive license from University of Toronto
to the patent portfolio that forms the basis of our Salinity Tolerance program.
In exchange for an upfront license fee, a royalty on revenues, and payment of
all costs associated with the patent portfolio, and subject to the University’s
right to use the technology for research and teaching purposes, we exclusively
control all for-profit research, development, commercialization and sublicensing
of the patented technology globally for all crops.
Abbott. We entered into a license and development agreement with Abbott in 2003
under which we have been granted limited exclusive rights to Abbott’s
portfolio of U.S. and foreign patents relating to the development of plant-based
sources of GLA, ARA and essential fatty acids. Under this agreement, we provide
Abbott with preferential access to commercial products from our GLA and ARA
safflower programs, as well as the right to receive royalty payments on product
sales to third parties, in exchange for the licenses to Abbott’s intellectual
property rights.
Dow AgroSciences. In December 2015, we announced the entry into a strategic
collaboration with Dow AgroSciences to develop and commercialize new yield traits
and trait stacks in corn. The collaboration leverages our platform of abiotic
stress traits with Dow AgroSciences’ enabling technology platforms, input
traits, regulatory
17
capabilities and commercial channels. As part of the strategic partnership,
we negotiated non-exclusive access to Dow AgroSciences’ EXZACT™
Precision Technology Platform to enhance and accelerate the development of trait
stacks. Dow AgroSciences has developed the EXZACT™ Precision Technology
Platform under an exclusive license and collaboration agreement in plants with
Sangamo BioSciences, Inc.
RKDA's Suppliers Net Income grew by
RKDA's Suppliers Net margin grew in Q2 to
139.36 %
14.96 %
RKDA's Suppliers Net Income grew by 139.36 %
RKDA's Suppliers Net margin grew in Q2 to 14.96 %
Arcadia Biosciences Inc's Suppliers Sales Growth
in Q2 2026 by Industry
Sources:
Arcadia Biosciences Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Arcadia Biosciences Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.